Physician profile
Mark S Collins
NPI 1962451021
$2,354.03
in general payments reported to CMS, 2019-2025
37 companies · $502 in 2025
The $502 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.07 · 2020: $324 · 2021: $338 · 2022: $226 · 2023: $872 · 2024: $80.66 · 2025: $502.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,297 · Education: $158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,296.50 |
| Education | $157.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $236.94 | 2021-2023 | Padcev, Tukysa |
| Amgen INC. | $211.08 | 2019-2025 | Imdelltra (Amg757), Lumakras |
| Pharmacyclics LLC, An Abbvie Company | $165.69 | 2020-2023 | Imbruvica |
| Abbvie INC. | $162.91 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $154.43 | 2020-2025 | |
| Genzyme Corporation | $122.59 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $105.69 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $102.58 | 2025 | Libtayo |
| Beigene USA, INC. | $86.23 | 2023 | Brukinsa |
| Rigel Pharmaceuticals, INC. | $81.79 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $80.12 | 2021-2025 | Opdivo |
| Daiichi Sankyo INC. | $75.72 | 2022-2025 | Datroway, Enhertu, Injectafer |
| Foundation Medicine, INC. | $61.39 | 2020-2023 | Foundationone Liquid Cdx |
| Pfizer INC. | $58.91 | 2020-2023 | |
| Incyte Corporation | $54.90 | 2021-2023 | Jakafi, Monjuvi |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $49.00 | 2025 | Xt Cdx |
| Jazz Pharmaceuticals INC. | $47.85 | 2023 | Zepzelca |
| Lilly USA, LLC | $46.04 | 2021-2025 | Verzenio, Jaypirca |
| Celgene Corporation | $44.23 | 2022-2023 | Reblozyl, Opdualag |
| Blueprint Medicines Corporation | $43.65 | 2021-2023 | Ayvakit |
| Merck Sharp & Dohme LLC | $35.83 | 2020-2023 | Lynparza, Keytruda, Welireg |
| Array Biopharma INC | $34.90 | 2023-2025 | Braftovi, Lorbrena, Mektovi |
| Astellas Pharma US INC | $34.73 | 2020-2023 | Padcev |
| Aveo Pharmaceuticals, INC. | $32.08 | 2021-2022 | |
| Acceleron Pharma, INC. | $21.57 | 2021 | |
| Emd Serono, INC. | $21.49 | 2023 | Tepmetko |
| Glaxosmithkline, LLC. | $20.97 | 2022 | |
| Adaptive Biotechnologies Corporation | $19.28 | 2022 | |
| G1 Therapeutics, INC. | $19.02 | 2023 | Cosela |
| Takeda Pharmaceuticals U.S.A., INC. | $16.76 | 2025 | Fruzaqla |
| Tersera Therapeutics LLC | $16.71 | 2023 | Zoladex |
| Adc Therapeutics America, INC. | $16.67 | 2023 | |
| Taiho Oncology, INC. | $15.95 | 2023 | |
| Morphosys, US INC. | $15.90 | 2023 | Monjuvi |
| Genentech USA, INC. | $15.65 | 2023 | Venclexta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.86 | 2021 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.